BALB/c mice transgenic (Tg) for the transforming rat neu oncogene (BALB-neuT) are genetically predestined to develop mammary carcinogenesis in a process similar to that in humans. We crossed HLA-A2.1/HLA-DR1 (A2.1/DR1) Tg mice with BALB-neuT mice to generate A2.1/DR1 × BALB-neuT triple Tg (A2.1/DR1 × neuT + ) mice, which represent an improvement over BALB-neuT mice for evaluating vaccination regimens to overcome tolerance against HER-2/neu. A vaccine formulation strategy, consisting of synthetic peptides from the rat HER-2/neu oncogene combined with granulocyte macrophage colony-stimulating factor, was highly effective in preventing the growth of established transplantable tumors in male A2.1/DR1 × neuT + mice. plus p776 exhibited long-lasting antitumor immunity. Our vaccine regimen also significantly delayed the outgrowth of mammary carcinomas in female A2
Introduction
HER-2/neu oncoprotein is overexpressed by a significant percentage of human carcinomas (1) , and this, at least in breast cancer, is associated with aggressive disease and enhanced metastatic potential (2) . Overexpression of HER-2/ neu poses a significant challenge to the design of effective cancer vaccines because it is recognized as a "self" molecule, and this implies that tolerance mechanisms against HER-2/ neu must be circumvented. Based on HER-2/neu transgenic (Tg) mouse models (3, 4) , we now know that T cells specifically recognizing an immunodominant epitope from the transgene (self) are rare and of lower avidity (4, 5) . These low-avidity T cells, upon efficient costimulation, have the capacity to develop antitumor responses (6) (7) (8) . However, higher-avidity T cells specific for epitopes encoded by the transgene can escape thymic deletion and are actively suppressed in the periphery of these mice by CD4 + CD25
high regulatory T cells (Treg; refs. 5, 8) . We (9) and others (4, 7, 8, 10, 11) have shown that removal of Tregs by various means has led to generation of antitumor immunity. Thus, the observation that T cells recognizing (self) tumor antigens persist in vivo suggests that elimination through tolerance is not complete and underscores the importance of defining potent vaccines specifically activating these cells.
Here, we evaluate the use of a vaccine mixture consisting of two immunogenic peptides corresponding to the HER-2 (776-790) (p776) CTL epitope (12) (13) (14) (15) (16) and the promiscuous p776 helper T cells (Th) epitope (17) (18) (19) (20) (21) . This is the first study, to our knowledge, defining the in vivo effect of combined vaccination with two HER-2/neu peptides representing CTL and Th epitopes on the dynamic relationship between vaccine-specific CTL and Th/Tregs in HER-2/neu tolerant A2.1/DR1 × neuT + and nontolerant A2.1/DR1 × neuT − littermates. In addition, we show that covaccination with p776 induces peptide-specific FasL + Th, which, via cell contact, induce apoptosis in Fas + Tregs within the tumor microenvironment. Our data strongly suggest that the therapeutic effect of this vaccine combination resides in increases in the intratumor frequency and activity of peptidespecific CTL and Th as a consequence of priming of this type of lymphocytes and removal of Tregs. Finally, the data also show that our vaccination schedule induces memory antitumor immunity, which is important considering the use of this peptide combination in clinical studies. Synthetic peptides. HER-2(435-443) (p435; ILHDGAYSL) and p776 (GVGSPYVSRLLGICL) peptides were synthesized and analyzed as described in our previous reports (13, 19) .
Materials and Methods

Generation
Antibodies. Antibodies used were as follows: anti-CD107a-FITC, anti-IFNγ-FITC, anti-CD95-FITC (anti-FAS), anti-CD178-PE (anti-FAS ligand), anti-CD127-PE, anti-mouse IgG2b-FITC and IgG2a-FITC, anti-HLA-DR-FITC, and Annexin V-PE (BD Biosciences Pharmingen); anti-CD4-APC, anti-CD8-APC, anti-Foxp3-APC, and anti-Foxp3-PerCP-Cy5.5 (eBioscience); anti-HLA-A2.1 (a gift from Prof. H.G. Rammensee, Department of Immunology, University of Tuebingen); PE-labeled HLA-A2.1 pentamer presenting the p435 epitope (PENT; Proimmune, Magdalen Centre, Oxford Science); and PE-labeled HLA-DR1 tetramer presenting the p776 epitope (Tm; Beckman Coulter).
Immunization protocol. Mice were immunized thrice every 5 d by s.c. injections at the base of the tail with 100 μg of peptide in 200 μL incomplete Freund's adjuvant (IFA) along with 100 ng of granulocyte macrophage colony-stimulating factor (GM-CSF) as described (9, 13) .
In vitro cytotoxicity assay. CD8 + T cells were isolated from immunized animals (9) and used as effectors against the indicated targets, as recently described (9, 13) . The HER-2 + TUBO mammary carcinoma cell line (5) was transfected to express HLA-A2.1 (TUBO.A2) by a method described in ref. (13) .
Therapeutic tumor models. (A) Mice were inoculated s.c. with 5 × 10 5 transplantable TUBO.A2 cells. Seven days later, peptides (single or in combination) in IFA were injected along with GM-CSF, as described (9, 13) . To test the capacity of the peptide combination vaccine to induce antitumor memory responses, mice were first vaccinated as above and, 8 wk later, were challenged with TUBO.A2 cells. Tumor size was monitored regularly every 4 d and was expressed as the product (in mm 2 ) of the perpendicular diameters of individual tumors. In some experiments, mice were treated intratumorally (days 30-40 after tumor inoculation) once with 200 μg of a blocking anti-FasL monoclonal antibody (mAb; IgG1 antimouse CD178, clone MFL3; BD Biosciences) or an isotype-matched control mAb (clone A19-3; BD Biosciences) in 100 μL PBS.
(B) Six-week-old female A2.1/DR1 × neuT + mice were vaccinated as above. Vaccinations were repeated monthly for 3 subsequent months (i.e., until these animals were 18 wk old). Mammary glands were inspected at weekly intervals to note tumor appearance. Progressively growing masses (mean diameter, >2 mm) were regarded as tumors. Tumor multiplicity was calculated as the cumulative number of incident tumors per total number of mice and was reported as mean ± SD (8) .
Isolation of tumor-infiltrating lymphocytes. This was essentially performed as recently described (23) .
Surface and intracellular staining. Supplementary Fig. S1 ). Equal numbers of Tregs and Th (2 × 10 6 cells in 2 mL) were distributed in 200 μL aliquots per well in a 96-well round-bottomed plate (Costar). After 24 h in a CO 2 incubator, cells were collected, stained with mAb, and analyzed by FACS.
Statistical analyses. The Student's t test was applied with a 95% confidence interval to determine the statistical significance of differences between groups, with P < 0.05 being considered significant.
Results
Immunogenicity of the peptide combination vaccine in HER-2/neu tolerant A2/DR1 × neuT + triple Tg. Our first task was to determine the immunogenicity of p435 in our HER-2/ neu tolerant male A2.1/DR1 × neuT + triple Tg (hereinafter called neuT + triple Tg) versus their HER-2/neu nontolerant littermates (A2.1/DR1 × neuT − ; hereinafter called neuT − littermates) given either alone or in combination with p776. Two major findings emerged from these studies ( Fig. 1Aa) : firstly, only marginal levels of cytotoxicity could be detected in neuT + triple Tg when p435 was given alone. In contrast, this peptide elicited strong cytotoxic responses in neuT − littermates (P < 0.001). Secondly, the levels of cytotoxicity in neuT + triple Tg were greatly enhanced when p435 was given together with p776 (P < 0.001 versus vaccination with p435 alone). As expected, the combined administration of these peptides further improved CTL responses in neuT − littermates (P < 0.05 versus vaccination with p435 alone). Cytotoxicity levels were correlated with the number of p776-specific CD8 + T cells, defined as HLA-A2.1/HER-2(9 435 ) pentamer + (PENT + CD8 + ) cells, in the spleen (Fig. 1Ab) . None of the mice (neuT + or neuT − ) injected with GM-CSF and IFA alone developed any detectable levels of cytotoxicity (data not shown).
Combined vaccination with p435 and p776 induces potent antitumor responses in tumor-bearing neuT + triple Tg. We then sought to investigate whether this vaccine formulation could act therapeutically against growing TUBO.A2 cells in male neuT + triple Tg. Animals were first inoculated with transplantable TUBO.A2 cells followed by injection 7 days later with the indicated HER-2/neu peptides. In control (PBS) neuT − mice, tumor grew fast and reached a size of ∼200 mm 2 after 20 to 25 days (Fig. 1Ba) . A moderate, but significant, delay of TUBO.A2 outgrowth was noticed in all seven neuT − littermates immunized with p435 alone (P < 0.05; Fig. 1Bb ), whereas a much stronger effect, upon vaccination with the peptide mixture, was seen in these animals (P < 0.001; Fig. 1Bc ). Tumor growth showed similar kinetics in control neuT + triple Tg (Fig. 1Ca) . However, vaccination with p435 had no effect on tumor growth in this group of animals (Fig. 1Cb) . In contrast, the majority of neuT + mice (7 of 11) rejected their tumors upon immunization with the combination of p435 plus p776 (P < 0.001; Fig.  1Cc ), whereas the remainders in this group showed a significant delay of tumor growth (P < 0.005; Fig. 1Cc ). In addition, the combination vaccine had no effect on the growth of wildtype TUBO cells, which do not express HLA-A2.1 (data not shown). To evaluate the potency of our peptide combination vaccine to induce a protective antitumor memory response, neuT + triple Tg were immunized with p435 plus p776 and challenged with TUBO.A2 cells 8 weeks later. As shown in Fig. 1Da , neuT + triple Tg were protected as efficiently as in experiments wherein the combination vaccine was given 7 days after tumor inoculation (Fig. 1Cc) , thus indicating that the antitumor T cells generated by the vaccine can last for at least 2 months. p776 was found to be immunogenic in naive neuT + triple Tg generating IFNγ producing CD4 + T cells ( Supplementary Fig. S2 ), yet it did not show any antitumor activity when used as a single-peptide vaccine in those animals inoculated with TUBO.A2 tumor cells (Fig. 1Db) .
p776 increases the percentages of functionally active p435-specific intratumor CD8 + T cells. We next studied whether this type of treatment could have an effect on the frequencies of p435-specific CD8 + T cells infiltrating the growing tumors. Tumors from mice with progressively growing tumors were harvested at a time point when their size reached ∼70 mm 2 ( Fig. 1Bb and Cb); in mice which finally rejected their tumors, these were removed at an early time point, following the beginning of their regression (usually on days 30-40; see Fig. 1Bc and Cc). As shown in Fig. 2 (Fig. 2Ba) . Importantly, CD107a mobilization and IFNγ production were detected only in a minority of PENT + CD8 + TIL in neuT + triple Tg (Fig. 2Aa) . Treatment with the combination vaccine (i.e., p435 plus p776) significantly increased the percentages of PENT + CD8 + TIL in both neuT − littermates and neuT + triple Tg (Fig. 2Ab , Bb, and C; P < 0.005). Strikingly, in neuT + triple Tg, almost all of the p435-specific CD8 + TIL were functionally active, as determined by intracellular IFN-γ and membrane CD107a staining (Fig. 2Ab) . Therefore, it seems that besides amplifying the anti-p435-specific CTL response the p776 vaccine also provides signals that reverse tolerance against HER-2/ neu-specific Fig. 3Aa and Ba). Interestingly, greater differences in the percentages of these CD4 + T-cell populations were observed after combined vaccination with p435 and p776. The Th/Treg ratio was increased up to 7-fold at the tumor site in neuT + triple Tg ( Fig. 3Ab and Ca). An increase of Th TIL was also revealed in neuT − littermates receiving the combination vaccine ( Fig. 3Bb and Cb). Interestingly, the increase in Th/Treg ratios was associated with a decrease in Treg TIL ( Fig. 3Ab and Bb). Analyses of splenocytes revealed increasing numbers of Tregs in neuT + mice 15 days after vaccination with p435 (day 15 versus day 1 after vaccination, P < 0.005), which were significantly decreased (P < 0.001) upon vaccination with p435 plus p776 (Fig. 3Da ). An analogous situation was also observed in neuT − littermates with a weak, but significant, increase in Tregs upon vaccination with p435 (day 15 versus day 1, P < 0.005) and a strong decrease of this population in the combined vaccination protocol (P < 0.001; Fig. 3Db Fig. S3 ).
Tregs are susceptible to FasL-Fas-induced apoptosis. It has been reported that Tregs, in contrast to Th cells, are susceptible to FasL-mediated cell death (25, 26 Fig. 5Bb and Bc), whereas only low percentages of apoptosis undergoing Treg TIL could be detected after vaccination with p435 alone (Fig. 5Ba and Bc) . In contrast to Treg TIL, low numbers of Annexin V + cells could be detected among Th TIL in either group of vaccinated neuT + triple Tg (Fig. 5Ba and Bb). Similar results (i.e., increased percentages of FasL + Th and Annexin V + Tregs upon vaccination with the peptide combination vaccine) were also observed in neuT − littermates ( Supplementary Fig. S4 ). To firmly confirm an interaction between FasL + Th and Fas + Treg TIL, resulting in increased apoptotic rates among the latter cell population, we isolated Th TIL from neuT + triple Tg vaccinated either with the peptide combination vaccine or with p435 alone and incubated Th from each group for 24 hours with Tregs isolated from p435-vaccinated neuT + triple Tg. The data from Fig. 5Cb and Cc show high percentages of Annexin V + Tregs (average, 72%) upon incubation with FasL + Th from p435 plus p776-vaccinated mice. In contrast, only a minor population of Tregs was Annexin V + upon incubation with Th from neuT + mice vaccinated with p435 alone (average, 5%; Fig. 5Ca and Cc).
In another model, we applied intratumoral injections with anti-FasL mAb in p435 plus p776-vaccinated neuT + triple Tg (n = 8) at a time period before tumor shrinkage (i.e., 30-40 days after tumor inoculation). In all these mice, tumor growth was promoted (Fig. 1Dc) . In contrast, intratumoral injections with an isotype-matched antibody did not influence tumor regression (compare Fig. 1Dc with Fig. 1Cc ). Therapeutic vaccination against spontaneous mammary tumors. Female neuT + triple Tg have a 100% penetrance of mammary carcinogenesis and follow similar kinetics of autochtonous tumor development as their parental BALBneuT animals (Fig. 6A) . We next evaluated the effect of HER-2/neu vaccination in the prevention of spontaneous mammary tumors in our female neuT + triple Tg. First, we studied the effect of p435 vaccination given to the mice at week 6 from birth when atypical hyperplasia is already evident in the mammary glands but before in situ carcinomas are seen (8) . The average number of tumors increased equally fast in both vaccinated as well as nonvaccinated control mice: at least one carcinoma (mean diameter, >2 mm) was palpable in each control (IFA+ GM-CSF) or p435+ IFA+ GM-CSF-vaccinated mouse by weeks 18 to 20, whereas by week 30, a tumor was palpable in all 10 mammary glands ( Fig. 6B and C) . Vaccination with the peptide combination vaccine delayed by almost 15 weeks the time required for these mice to develop tumors, extending both mouse disease-free survival and reducing tumor multiplicity ( Fig. 6B and C; P < 0.001). Importantly, 30% of the animals vaccinated with p435 plus p776 were tumor free (Fig. 6B ) at 1 year of age, when the experiment ended.
Discussion
In this study, we explored the possibility that p776-activated Th cells assist in breaking tolerance against the HER-2/neu CTL epitope p435, which represents a tumor rejection molecule (13) . In our study, neither p435 nor p776 showed antitumor activity when used as single-peptide vaccines in HER-2/ neu tolerant male A2.1/DR1 × neuT + triple Tg with established TUBO.A2 tumors. By contrast, when immunized with the CTL plus Th HER-2/neu peptide combination vaccine, these animals retarded tumor growth or became long-term survivors by converting tolerogenic into immunogenic conditions. Additionally, we analyzed individual tumors from triple Tg belonging to the CTL-vaccinated group and uncured or cured CTL plus Th-vaccinated groups for immune effector capability. The data showed that the regressing tumors were infiltrated by a significantly higher number of vaccinespecific CD8
+ CTL with lytic capabilities and IFNγ production. As concerns the intratumoral presence of CD4 + T cells, we also observed an increased expression of p435-specific CD4 + T cells producing IFNγ in the regressing tumors of triple Tg vaccinated with both peptides compared with the single CTL peptide-vaccinated animals. TIL in various human cancers have been shown to be capable of inhibiting tumor growth, and their presence has occasionally been associated with an improved prognosis (27) (28) (29) . Moreover, in accordance with our data that show that IFNγ-secreting CD4 + T cells infiltrated regressing tumors, recent studies have suggested that concurrent infiltration by Th1 cells have a positive effect on clinical outcome (30, 31) . However, very little is known about the factors/mechanisms that drive these T cells to migrate inside a tumor. The IFNγ secretion we detected at the systemic level ( Supplementary Fig. S2 ) could play a determinant role in this process. Indeed, Nakajima and colleagues have reported that, in IFNγ-deficient mice, functional T cells were generated but failed to migrate to tumor sites (32) .
Vaccines directed against HER-2/neu have proved to be successful in the prevention of tumor growth in transplantable tumor models as well as in HER-2/neu Tg mice (33) (34) (35) (36) . The induction of effective HER-2 antitumor immunity seems to rely on different mechanisms, depending on the tumor model, and there is evidence that both antibodies and CTLs play a role in HER-2 tumor protection after DNA vaccination (33, 36) . Thus, at this stage, we cannot rule out the possibility that p776-driven Th cells could assist in HER-2/neu-specific antibody production, thereby also contributing to HER-2/neu tumor protection.
When vaccinated but in the absence of the p776 Th peptide, NeuT + triple Tg contained low, but measurable, frequencies of such p435 peptide-specific CD8 + T effectors, showing an ongoing vaccine-specific immune response even in the context of a strong tolerogenic environment. Notably, our One major finding in our study is that the number of local Tregs can be modulated by effector Th cells. It has recently been shown that an increased effector to Treg ratio in the tumor following CTLA4 blockade and GM-CSF combination immunotherapy correlates with improved survival of tumorbearing mice (23) . We have observed a tremendous increase in the percentage of FasL + cells among the CD4 + Foxp3 − tumor-infiltrating Th in neuT + triple Tg immunized with the peptide combination vaccine, which, upon cell-cell interaction, mediated apoptotic effects in Fas + Tregs. To this end, it is worth mentioning that the number of Annexin V + Tregs was always higher than their percentage of Fas expression (Fig. 5) . One possible explanation for this could be that, in addition to Fas-FasL, other death receptors (e.g., DR5) may also be triggered by their ligands expressed on Th. Another possibility, which is based on a recent report (37) , could be that our vaccine-activated Th may induce (HLA-DR + ) Treg death through production of Granzyme B. These possibilities are now under investigation.
In agreement with our finding, Chen and colleagues (38) have recently shown susceptibility of Tregs to soluble FasLinduced apoptosis. Thus, our data support the idea that a more potent antitumor response at the tumor site can be achieved via a vaccination regimen generating high numbers of FasL-expressing intratumoral CD4 + Th, which keep Tregs in check by modulating their survival via Fas-mediated killing, which in turn results in higher ratios of Th to Tregs. In this way, we provide a simple method for depleting Treg at the tumor site without the need to exogenously administer Treg-modulating agents, which may cause toxic effects (8, 38) .
Although the significance of CD4 + T cells in antitumor CTL responses is recognized, only a few mechanisms have been put forward to explain their positive effects on effector function of CTL (12) . In this study, we have shown that, in the tumor microenvironment, HER-2/neu peptide-specific Th potentiate HER-2/neu peptide-induced antitumor responses of CTL via mechanisms including increased IFNγ production and elimination of Treg through FasL-Fas interaction. These mechanisms may have direct implications on the outcome of immune responses to tumors after combined immunotherapy regimens. Surely, further work is needed to precisely elucidate the mechanisms by which Th cells enhance the functional program of CTL and to further delineate the physiologic role of this protective effect.
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